GGrantIndex
← Search

PROVIGIL (MODAFINIL) TREATMENT IN SLEEP APNEA

$0M01FY2000RRNIH

Beth Israel Deaconess Medical Center, Boston MA

Investigators

Linked publications & trials

Abstract

The primary objective of this study is to determine the efficacy and safety of PROVIGIL 400 mg/d as a treatment for residual excessive daytime sleepiness (EDS) in obstructive sleep apnea patients who are documented regular users of nasal CPAP treatment. The secondary objective is to determine whether PROVIGIL treatment affects patient vigilance, functional capacity, or use of CPAP.

View original record on NIH RePORTER →